Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Sheiner PA et al. | Acute renal failure associated with the use of ibuprofen in two liver transplant recipients on FK506. | 1994 | Transplantation | pmid:7513099 |
Shin BH et al. | Regulation of anti-HLA antibody-dependent natural killer cell activation by immunosuppressive agents. | 2014 | Transplantation | pmid:24342979 |
First MR and Fitzsimmons WE | New drugs to improve transplant outcomes. | 2004 | Transplantation | pmid:15201693 |
Migita K et al. | FK506 markedly enhances apoptosis of antigen-stimulated peripheral T cells by down-regulation of Bcl-xL. | 1999 | Transplantation | pmid:10532544 |
Yoon SH et al. | CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III). | 2013 | Transplantation | pmid:23364483 |
Ravindran VK et al. | Insulin hyposecretion in nondiabetic, tacrolimus-treated renal transplant recipients more than 6 months posttransplantation. | 2009 | Transplantation | pmid:19543067 |
Morrissey PE et al. | Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. | 1997 | Transplantation | pmid:9089224 |
Sheiner PA et al. | Increased risk of early rejection correlates with recovery of CD3 cell count after liver transplant in patients receiving OKT3 induction. | 1997 | Transplantation | pmid:9355846 |
Karlsson H and Nässberger L | FK506 suppresses the mitogen-induced increase in lymphocyte adhesiveness to endothelial cells, but does not affect endothelial cell activation in response to inflammatory stimuli. | 1997 | Transplantation | pmid:9355847 |
Reding R et al. | Conversion from cyclosporine to FK506 for salvage of immunocompromised pediatric liver allografts. Efficacy, toxicity, and dose regimen in 23 children. | 1994 | Transplantation | pmid:7507272 |
Storb R et al. | FK-506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors. | 1993 | Transplantation | pmid:7692635 |
McDiarmid SV et al. | A comparison of renal function in cyclosporine- and FK-506-treated patients after primary orthotopic liver transplantation. | 1993 | Transplantation | pmid:7692636 |
Osowski CL et al. | Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. | 1996 | Transplantation | pmid:8610430 |
Butani L et al. | Amelioration of tacrolimus-induced nephrotoxicity in rats using juniper oil. | 2003 | Transplantation | pmid:12883183 |
David-Neto E et al. | Longitudinal Pharmacokinetics of Tacrolimus in Elderly Compared With Younger Recipients in the First 6 Months After Renal Transplantation. | 2017 | Transplantation | pmid:27482958 |
Marcén R et al. | Lumbar bone mineral density in renal transplant patients on neoral and tacrolimus: a four-year prospective study. | 2006 | Transplantation | pmid:16570003 |
Ciancio G et al. | A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. | 2006 | Transplantation | pmid:16570006 |
Reddy KS et al. | Simultaneous kidney-pancreas transplantation without antilymphocyte induction. | 2000 | Transplantation | pmid:10653379 |
Sood P et al. | Management and outcome of BK viremia in renal transplant recipients: a prospective single-center study. | 2012 | Transplantation | pmid:23018881 |
Alonso-Arias R et al. | CD127(low) expression in CD4+CD25(high) T cells as immune biomarker of renal function in transplant patients. | 2009 | Transplantation | pmid:19667968 |
Galliford J et al. | ABO incompatible living renal transplantation with a steroid sparing protocol. | 2008 | Transplantation | pmid:18852653 |
Jevnikar A et al. | Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure. | 2008 | Transplantation | pmid:18852662 |
Ninova D et al. | Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: differential intragraft expression of transforming growth factor-beta1 and alpha-smooth muscle actin. | 2004 | Transplantation | pmid:15316360 |
Naesens M and Sarwal MM | Monitoring calcineurin inhibitor therapy: localizing the moving target. | 2010 | Transplantation | pmid:20458272 |
Watson MJ et al. | Renal function impacts outcomes after intestinal transplantation. | 2008 | Transplantation | pmid:18622288 |
McLaren A | Tacrolimus pharmacogenetics: bringing the laboratory into the clinic. | 2003 | Transplantation | pmid:14705621 |
Amundsen R et al. | Rimonabant affects cyclosporine a, but not tacrolimus pharmacokinetics in renal transplant recipients. | 2009 | Transplantation | pmid:19384170 |
Jun KR et al. | Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea. | 2009 | Transplantation | pmid:19384171 |
Curran CF et al. | Acute overdoses of tacrolimus. | 1996 | Transplantation | pmid:8932293 |
Roberts CA et al. | Asymmetric cardiac hypertrophy at autopsy in patients who received FK506 (tacrolimus) or cyclosporine A after liver transplant. | 2002 | Transplantation | pmid:12364862 |
Fukushima D et al. | Epstein-Barr virus--associated posttransplantation lymphoproliferative disorder with tacrolimus metabolism deterioration in infants after living-donor liver transplantation. | 2015 | Transplantation | pmid:24846306 |
Egli A et al. | Comparison of the effect of standard and novel immunosuppressive drugs on CMV-specific T-cell cytokine profiling. | 2013 | Transplantation | pmid:23274966 |
Hu H et al. | Effect of immunosuppressants on T-cell subsets observed in vivo using carboxy-fluorescein diacetate succinimidyl ester labeling. | 2003 | Transplantation | pmid:12698107 |
Hebert MF et al. | Interpreting tacrolimus concentrations during pregnancy and postpartum. | 2013 | Transplantation | pmid:23274970 |
Fujishiro J et al. | Immunologic benefits of longer graft in rat allogenic small bowel transplantation. | 2005 | Transplantation | pmid:15665767 |
Thai NL et al. | Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes. | 2006 | Transplantation | pmid:17198247 |
Thai NL et al. | Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: Correlation between low T-cell responses and infection. | 2006 | Transplantation | pmid:17198253 |
Hewitt CW and Black KS | Comparative studies of FK506 with cyclosporine. | 1988 | Transplantation | pmid:2458644 |
Vadivel N et al. | Tacrolimus dose in black renal transplant recipients. | 2007 | Transplantation | pmid:17460575 |
Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Drug levels in PHAs who receive liver transplants. | 2003 Apr-May | TreatmentUpdate | pmid:17216847 | |
Kunz J and Hall MN | Cyclosporin A, FK506 and rapamycin: more than just immunosuppression. | 1993 | Trends Biochem. Sci. | pmid:7694398 |
Cardenas ME et al. | Signal-transduction cascades as targets for therapeutic intervention by natural products. | 1998 | Trends Biotechnol. | pmid:9807840 |
Snyder SH et al. | Neural actions of immunophilin ligands. | 1998 | Trends Pharmacol. Sci. | pmid:9509898 |
Liu J | FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. | 1993 | Trends Pharmacol. Sci. | pmid:7692652 |
Chang JY et al. | FK506 and rapamycin: novel pharmacological probes of the immune response. | 1991 | Trends Pharmacol. Sci. | pmid:1710854 |
Sommerer C et al. | Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial. | 2016 | Trials | pmid:26888217 |
Nashan B et al. | Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial. | 2015 | Trials | pmid:25873064 |
Bajetta E et al. | Merkel cell carcinoma after liver transplantation: a case report. | 2007 May-Jun | Tumori | pmid:17679476 |
Vennarecci G et al. | [Acute liver toxicity of antiretroviral therapy (HAART) after liver transplantation in a patient with HIV-HCV coinfection and associated hepatocarcinoma (HCC)]. | 2003 Jul-Aug | Tumori | pmid:12903579 |
Tümgör G et al. | A case of uneventful ABO-incompatible liver transplantation from a deceased donor managed with routine immunosuppressive treatment. | 2014 | Turk J Gastroenterol | pmid:25599790 |